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a  b  s  t  r  a  c  t
Although  empirical  studies  show  that  protection  against  inﬂuenza  infection  in humans  is  closely  related  to
antibody  titres,  inﬂuenza  epidemics  are  often  described  under  the  assumption  that  individuals  are  either
susceptible  or  not. Here  we  develop  a model  in  which  antibody  titre  classes  are enumerated  explicitly  and
mapped  onto  a variable  scale  of  susceptibility  in  different  age  groups.  Fitting  only  with  pre-  and  post-wave
serological  data  during  2009  pandemic  in Hong  Kong,  we  demonstrate  that with  stratiﬁed  immunity,  the
timing  and  the  magnitude  of the  epidemic  dynamics  can  be  reconstructed  more  accurately  than  is possible
with  binary  seropositivity  data.  We  also  show  that  increased  infectiousness  of  children  relative  to  adults
and age-speciﬁc  mixing  are  required  to reproduce  age-speciﬁc  seroprevalence  observed  in Hong  Kong,
while  pre-existing  immunity  in  the elderly  is not.  Overall,  our  results  suggest  that  stratiﬁed  immunity
in  an  aged-structured  heterogeneous  population  plays  a signiﬁcant  role in  determining  the  shape  of
inﬂuenza  epidemics.
©  2017  Published  by Elsevier  B.V.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Traditional syndromic surveillance for inﬂuenza has substantial
public health value in characterizing epidemics. For example, by
comparing syndromic incidence for one year with previous years,
accurate alerts can be issued for possible excessive demands on
health services (Ortiz et al., 2009). Epidemic models are commonly
used in combination with surveillance data for pandemic preven-
tion, control, forecasting, early characterization of novel strains,
and the investigation of drivers of transmissibility of inﬂuenza
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(Heesterbeek et al., 2015). However, less insight can be obtained
from these data than might be expected because the relationship
between syndromic data and the true infection events can vary
from one population to another and from one year to another (e.g.,
variability in reporting rates), and thus the actual infection number
is difﬁcult to estimate.
Serosurveillance of inﬂuenza provides a potentially more accu-
rate way  to estimate actual numbers of infected cases (Cauchemez
et al., 2012; Briand et al., 2011; Lipsitch et al., 2011). Recent studies
rely on combining serological test results with syndromic data
from traditional surveillance within epidemic models to make
inference on epidemiological processes of inﬂuenza (Birrell et al.,
2011; Dorigatti et al., 2013; Baguelin et al., 2013). For example,
Dorigatti et al. (2013) showed that the third wave of pandemic
H1N1 infection in the UK could be explained by the increased
transmission and short-term age-speciﬁc immune waning after
jointly ﬁtting the model to inﬂuenza-like illness (ILI) incidence and
http://dx.doi.org/10.1016/j.epidem.2017.03.003
1755-4365/© 2017 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the serological data. However, up to now, these studies treated
serological assays as a dichotomous variable, with individuals
classiﬁed as uninfected and susceptible if their titre is below a
certain threshold and infected and immune if their titre is above
that threshold. Typically, a titre of 1:40 (dilution ratio) is used
as the threshold because this titre was previously estimated to
generate about 50% immune protection (referred to as TP50)
(Hobson et al., 1972; Coudeville et al., 2010).
However, certain limitations in the use of such threshold data
make the further assessment of epidemiological mechanisms more
difﬁcult. First, a wide range of antibody boosting (deﬁned as the
increase of the antibody titres in response to infections) has been
observed in serological studies (Miller et al., 2010), resulting in
the underestimation of infection incidence because low titres are
ignored (Cauchemez et al., 2012; Wu and Riley, 2014; Wu  et al.,
2014). Moreover, the protective titre TP50 only provides partial
protection against infection and could differ by virus strains and
host ages (Black et al., 2012). Together, the incidence is not able to
be accurately captured by the depletion of susceptibles within the
models using threshold data. Despite the widespread availability of
serological data from many recent inﬂuenza serosurveillance stud-
ies (Achonu et al., 2011; Dudareva et al., 2011; Iwatsuki-Horimoto
et al., 2011; Miller et al., 2010; Waalen et al., 2010; McVernon
et al., 2010; Reed et al., 2012), current epidemic models have
thus far not explicitly represented individual antibody titre levels
and its correspondence with immunity (Heesterbeek et al., 2015).
Therefore, a more understanding of how serological responses and
protection of individuals affect transmission in a heterogeneous
mixing population, is a current scientiﬁc goal and should facilitate
improved predictive models of inﬂuenza (Shaman and Karspeck,
2012; Shaman et al., 2013).
Here, we propose a reﬁnement of the concept of the stratiﬁed
immunity within an epidemic model for inﬂuenza transmissions.
We explicitly enumerate all possible titres in standard haemag-
glutination inhibition (HI) assays and map  them onto a variable
scale of susceptibility. By coupling the epidemic model with sero-
logical responses in different age groups, we are able to investigate
key biological mechanisms in stratiﬁed immunity, such as antibody
boosting and protection in greater detail. We  are also able to assess
the epidemiological factors, among which age-speciﬁc prevalence
was produced.
2. Results
2.1. Crude patterns of titre difference
We  ﬁrst compared the overall pattern of antibody titres between
the baseline and follow-up measurements in the study. The
inﬂuenza pandemic started in early May  2009 with the ﬁrst con-
ﬁrmed case announced on 1st of May. Virologically conﬁrmed
incidence of infection reached its maximum during late September.
We obtained HI antibody titres from 523 individuals between 4 July
2009 and 28 September 2009 as baseline titres, and HI titres from
465 individuals during the follow-up (between 11 November 2009
and 6 February 2010) (Fig. S1). We  deﬁned T1 to be the average of
the time of sampling for the baseline study (11 August 2009) and T2
to be the average day of the follow-up (22 December 2009). Changes
in the overall distribution of titres indicated that there has been a
substantial epidemic during this period. Between T1 and T2, the
proportion of the study population without detectable antibodies
decreased from 90.1% to 80.0% with the increase in detectable titres
being distributed more to the individuals with higher titres (Fig. S2).
For example, increases in titres between 80 and 320 accounted for
65.1% of the decrease observed in the proportion with undetectable
titre.
2.2. Epidemic model with stratiﬁed immunity
We constructed an age-structured multi-level susceptible-
infected-recovered-susceptible (SIRS) epidemic model in which all
antibody titres were represented explicitly (referred to here as the
model A, the full titre model; see Methods and Fig. S3). Using the
titre model with age mixing, we  ﬁtted the titre model to the sero-
logical data during the pandemic. The fraction of the elderly (≥65
years old, referred as yo) with pre-existing antibodies was  set to
be twice as large as other persons based on previous studies (Wu
et al., 2014; Xu et al., 2011; Riley et al., 2011). Aggregated across
age groups, the model was able to reproduce antibody proﬁles with
good accuracy (Fig. 1). Model predicted titres at T1 were slightly
lower than certain observed baseline titres but overall were consis-
tent with our observations. At T2, the proportions of each predicted
titres fell into or overlapped with the 95% conﬁdence interval of the
observed follow-up titres. Children (<20 yo) demonstrated higher
antibody titres during follow-up while lower titres were present in
the middle-aged adults (40–64 yo) and elderly (≥65 yo). Given the
small sample size for the elderly and that pre-existing immunity
was not well known, the model ﬁt showed a good agreement with
the observed titres across age groups.
2.3. Serological responses and clinical protection
We found differences in age-speciﬁc antibody boosting follow-
ing the infection. The average antibody boosting was highest among
children, with 62.2 [31.6–128.0] fold increase in titres (AbB1 = 5.96
[4.98–7.00]; see Table 1). The boosting decreased by age until
middle-aged adults to 13.7 [8.17–24.3] fold increase (AbB3 = 3.78
[3.03–4.60]), which was signiﬁcantly lower than children (non-
overlapping 95% credible intervals). Conversely, the elderly showed
higher boosting than middle-aged adults. However, although there
was a suggestion that older adults had less protection for a given
antibody level, we  did not ﬁnd strong evidence for age-speciﬁc
correlates of immune protection. The protective titres which were
associated with 50% protection (TP50) had overlapping 95% credi-
ble intervals and were therefore not signiﬁcantly different. Among
children and adults (≤65 yo), the average protective titres were
between 20 and 80, which were consistent with previous studies
(Hobson et al., 1972; Coudeville et al., 2010; de Jong et al., 2003).
For the elderly, a weaker protective titre was found between 160
and 320, but with a wide credible interval.
2.4. Reconstructing epidemic dynamics
Fitting only serological data, the full titre model was  able to
reproduce the peak time and the cumulative incidence of the 2009
pandemic in Hong Kong during the initial wave. The average inci-
dence increased rapidly after August and reached the peak on 3
October (Fig. 2A) (note that the peak of the average incidence was
slightly different than the average of the peak time on 13 Oct. 2009
[14 Sep. – 29 Nov.]), which was  1–2 weeks later than the observed
peak incidence between middle and the end of September using
either the hospitalization or laboratory conﬁrmed cases (Riley et al.,
2011; Wu et al., 2010). Nevertheless, the few weeks’ delay can be
explained by the temporal offset between infection and serological
boosting (Miller et al., 2010; Mak  et al., 2010; Baguelin et al., 2011).
An asymmetric longer tail in the epidemic proﬁle after November
was reproduced until the disease faded out in February. The cumu-
lative incidence from 1 May  to T2 was 22.3 % [15.5 % −28.1 %] (Table
S1), which was  consistent with previous estimation (22.5% for
3–59 yo in Wu  et al., 2014).
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Fig. 1. Comparison of titre model ﬁt (gray) and observed (blue) age-stratiﬁed data for baseline and follow-up surveys. The top row describes the pattern for the entire
population, while the bottom four rows describe patterns for speciﬁc age groups. Vertical bars indicate 95% binomial conﬁdence intervals (observed) and 95% region of
posterior credibility (model). Left y-axis indicates the percentage with undetectable titre. Right y-axis indicates percentages in other titre classes. Note left and right y-axis
are  different scales. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of the article.)
2.5. Underestimation of infection incidence from seroprevalence
The predicted seroprevalence, deﬁned as the proportion of the
population with titres above or equal to the threshold titre 40,
from the full titre model increased from 2.7 % [2.3 − 3.4 %] (T1)
to 20.4 % [15.1 − 24.3 %] (T2), which was slightly lower than the
baseline titres 8.9 % [6.7 − 11.6 %] but in very good agreement with
the follow-up titres 20.6 % [17.2 − 24.5 %] (Table S2 and Fig. S4A).
Interestingly, the average increase of seroprevalence (18.1%) from
1 May  to T2 was 18.8% less than the average cumulative incidence,
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Fig. 2. Disease and serological dynamics of the titre model simulation. Dynamics were reconstructed using 400 random samples from the posterior distributions of the
parameters. (A) The disease dynamics calculated using the titre model. Bold blue, seropositive individuals, deﬁned as individuals with titres ≥40. Thin blue, seronegative
individuals, deﬁned as individuals with titres <40. Solid lines give the posterior mean, while dashed lines give 95% credible intervals. The percentage of the infected individuals
is  shown in red. Vertical lines indicate average recruiting time T1 and T2 during the periods of baseline and follow-up surveys. Gray bars represent the weekly number of
laboratory conﬁrmed cases of 2009 pandemic in Hong Kong. (B) The serological dynamics simulated during the outbreak using the titre model. Darker colour represents a
lower  proportion and lighter represents a higher proportion of the population with a given antibody titre. (C) The disease dynamics calculated with the threshold model
using  the classic deﬁnition of seropositivity (1:40). Colours are the same as in (A). (D) The serological dynamics simulated during the outbreak using the threshold model.
Darker  colour represents a lower proportion and the lighter one represents a higher density in the population. Note that the average of the peak time obtained from the
posterior sampling is slightly different from the peak of the average incidence as shown in (A) and (C). (For interpretation of the references to colour in this ﬁgure legend,
the  reader is referred to the web version of the article.)
indicating that a proportion of nearly 20% of infected individuals
was underestimated using seroprevalence, either because individ-
uals had low antibody boosting to titres fell below 40, or were
previously seropositive but were still infected or reinfected later
due to partial protection (e.g., mostly between titres 40-80, see
Fig. 2B).
2.6. Model comparison
To compare the full titre model (model A) with the epidemic
model that only produced threshold predictions, we  performed
similar analyses using the susceptible-infected-recovered (SIR) epi-
demic model (referred to here as the model E, the threshold model;
see Methods) ﬁtting to individual seropositivity data aggregated
from the same serological titres proﬁle using the threshold titre.
Speciﬁcally, all titre values below 40 were assigned to be seroneg-
ative and all other titre values were assigned to be seropositive.
The full titre predictions were also transformed into threshold
results. Thus the similarities between model predictions and the
individual seropositivity dataset were able to be evaluated for both
models. Deviance Information Criterion (DIC) was  used to mea-
sure the ﬁtness of both models to the seropositivity data (see
Methods). Models with smaller DIC were preferred. Generally, dif-
ferences larger than 5 are substantial. We  found that model A
was a better explanation of these data than the threshold model
E (DIC =−11.5).
For both models, the effects of each serological and epidemi-
ological variable were also evaluated. Three alternative restricted
titre models, each with age-independent antibody boosting (model
B), age-independent antibody protection (model C) and without
the relative infectivity (model D), and one alternative threshold
model without the relative infectivity (model F) were also com-
pared with model A (see Table 2 for full model descriptions and
comparison results). All of the models were able to infer a single
peak epidemic between T1 and T2 with the same age mixing and
pre-existing seroprevalence. We found that the model C was the
best-ﬁt model whereas the model A was comparable to the model
C (DIC = 2.6) and both models demonstrated similar age-speciﬁc
antibody boosting (Table S3). Age-dependent antibody boosting
(model A versus B) improved the model ﬁt (DIC =−7.0) while
age-dependent antibody protection (model A versus C) not. This
further conﬁrmed the signiﬁcant differences in age-speciﬁc anti-
body boosting but not among age-speciﬁc protection in the full titre
model (Table 1). We  also demonstrated that the relative infectivity
of children (model A versus D) greatly improved the ﬁt of the titre
model (DIC =−38.5).
2.7. Determining age-speciﬁc seroprevalence
The titre model with age contact mixing allowed us to explore
the effects of different factors on determining age-speciﬁc infection
pattern. As reported from previous studies (Wu  et al., 2010; Riley
et al., 2011), we found that the largest increase of the estimated
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seroprevalence was found in children from 2.9 % [2.1 − 4.4 %] to
35.8 % [25.3 − 42.7 %], and the least change was present in the
elderly from 4.1 % [4.0 − 4.2 %] to 7.1 % [5.5 − 8.5 %] (Table S2 and
Figure S4A). To test whether the high pre-existing immunity
determined the low incidence in the elderly, we reproduced
the seroprevalence changes, in which elderly had only the same
initial antibody protection as other age groups and compared the
increase of seroprevalence from 1 May  to T2. Despite removing
this age-dependent pre-existing immunity, a similar age-speciﬁc
serological pattern was found, indicating that pre-existing immu-
nity in the elderly was not the critical factor to explain the lower
incidence in this age group in Hong Kong (Fig. 3A). When the
fraction of elderly with pre-existing antibodies was  set to be 4
times that of other age groups, seroprevalence was  reduced not
only in the elderly but also in all the other groups. We  further
investigated whether the pattern was determined by age-speciﬁc
antibody boosting. However, the cumulative incidence in the
elderly also demonstrated the lowest proportion of infection in
the population (Table S1). We  then re-ﬁtted the model, in which
antibody boosting was the same for all age groups (model B). A
similar age-speciﬁc pattern was still shown (Fig. 3B). Interestingly,
when we re-ﬁtted the model without relative infectivity of chil-
dren (model D), the seroprevalence of children largely dropped to
below young and middle-aged adults but seroprevalence in adults
including the elderly was slightly increased (Fig. 3C). Together,
these suggested that relative infectivity of children to adults and
age contact mixing, rather than pre-existing immunity in elderly
or differences in age-speciﬁc antibody boosting, were required to
explain the age-speciﬁc infection pattern in Hong Kong.
2.8. Delay in the peak incidence
The different epidemic dynamics between the full titre and
threshold model highlighted critical challenges with the use of
seroprevalence for estimating the cumulative incidence using the
classical threshold approaches. Despite the similar seroprevalence
between the threshold model E and the observed data (Table S2 and
Fig. S4B), the threshold model estimated that the average incidence
reached its peak on 6 Nov. (note the peak of the average incidence
was slightly different than the average of the peak time: 5 Nov. [23
Sep.–30 Nov.]), which was nearly one and a half months later than
the reported incidence peak (Wu et al., 2010; Riley et al., 2011)
(Fig. 2C). In the threshold model, because all the infected individ-
uals were assumed to be seropositive after infection (Fig. 2D), the
amount of disease incidence not detected by seropositivity, was
not identiﬁable; as a result, the cumulative incidence was 17.1 %
[12.9 – 23.0 %] at T2 (Table S1), which was 23.3% lower than the
titre model even though both models predicted similar seropreva-
lence at T2 (Fig. S4). Thus, to produce the reduced ﬁnal size of
incidence, a lower R0 (or transmission rate) was estimated as 1.19
[1.16–1.25] (Table 1) by the threshold model, resulting in a substan-
tial delayed incidence peak (Fig. 4). We  further tested whether peak
time could be reconstructed without the delay in threshold model
if the cumulative incidence was not underestimated. We  re-ﬁtted
the predicted seroprevalence to the cumulative incidence gener-
ated from the titre model at T2 by changing only R0. The results
demonstrated that if all the incidence was able to be identiﬁed in
seroprevalence without underestimation, the key epidemiological
parameter R0 would be restored (1.23 [1.20–1.30]) and a similar
epidemic curve could be recovered (Fig. 4).
2.9. Sensitivity analysis
We  tested the robustness of our conclusions to a key sensitiv-
ity, by simulating the disease dynamics with different numbers of
initial infectious seeds in the population on 1st May. The full titre
Fig. 3. Changes in age-speciﬁc seroprevalence under different assumptions on anti-
body boosting and the relative infectivity of children. (A) Changes in seroprevalence
calculated using the titre model with full parameter sets (model A) from the ﬁrst day
of  the pandemic until the follow-up recruiting time T2. Blue, the titre model with
pre-existing immunity in the elderly set to twice that of other age groups (default
setting). Red, the titre model with reduced pre-existing immunity in the elderly and
all  age groups have the same seroprevalence. Green, the titre model with higher
pre-existing immunity in the elderly set to 4 times that of other age groups. (B)
Changes of the seroprevalence calculated using the titre model with the same anti-
body boosting among different age groups (model B). Colours are the same as in
(A).  (C) Changes of the seroprevalence calculated, using the titre model without the
increased relative infectivity of children (model C). Colours are the same as in (A).
Note that the changes in seroprevalence in model C were measured from the ﬁrst
day  of the pandemic until the follow-up recruiting time T2 plus additional 60 days
to  adjust for the delay of the peak. Similar patterns of seroprevalence were able to
be  produced if T2 was used instead of T2 plus 60 days. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version
of  the article.)
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Fig. 4. The seroprevalence and cumulative incidence by time reconstructed from the
models outputs. Gray, solid and dashed lines represent seroprevalence and cumu-
lative incidence produced by the full titre model (model A). Red, solid and dashed
lines represent seroprevalence and cumulative incidence produced by the threshold
model (model E). The slight difference between cumulative incidence and the sero-
prevalence in the threshold model is caused by the assumption that only healthy
persons (individuals not in infected status), would participate in the serosurveil-
lance survey. The blue line represents the seroprevalence produced by re-ﬁtting the
threshold model to the cumulative incidence generated from the full titre model at
T2.  The dot represents the time when the maximum slope is achieved, correspond-
ing to the peak of the respected epidemic curve. (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the web version of the article.)
model was more robust to changes in initial infectious seeds than
the threshold model. For the numbers of initial infectious seeds
that allowed the titre model to produce the proper peak time simi-
lar to the observed reports (e.g., for initial infectious seeds between
10 and 30), the threshold model systematically reproduced a more
delayed epidemic peak compared to the titre model (Fig. S5).
2.10. Effective reproductive number
The titre model allowed us to deﬁne the effective reproductive
number RB in the presence of pre-existing antibodies and compared
it to RC, deﬁned as the effective reproductive number using the
threshold model E. RB declined slowly from 1.22 [1.16–1.28] in the
ﬁrst four months of the outbreak and dropped rapidly below one
during September and October (corresponding to the time of peak
incidence); Whereas RC declined from a lower initial number 1.19
[1.16–1.25] and lasted about 1 month longer before dropping to 1
(Fig. 5), resulting in a reduced cumulative incidence with a delayed
incidence peak. Both effective reproductive numbers ended at 0.82,
conﬁrming that similar seroprevalences from models were present
after the outbreak.
3. Discussion
Using time series cross-sectional serosurveillance data, we
have demonstrated that explicitly representing stratiﬁed immunity
improved our ability to explain inﬂuenza transmission dynamics.
By representing partial protection and the differential boosting
of antibodies after infection, we obtained a more accurate epi-
demic curve in terms of peak time, incidence and the shape of
the tail. With partial protection, individuals with weak to medium
immunity could still be infected or reinfected, which has been
observed (Camacho et al., 2011). It is likely that the longer tail of
disease incidence observed in inﬂuenza pandemic in Hong Kong
after December and in seasonal inﬂuenza in the past several years
(Russell et al., 2016) may  reﬂect these reinfection dynamics gener-
ated by partial protection in the population.
Fig. 5. Comparison of the effective reproductive numbers between the titre and
threshold models. Blue, the 95% credible interval of the reproductive number RB
estimated from the titre model with age-speciﬁc serological parameters. Red, the
95% credible interval of the reproductive number RC estimated from the threshold
model with the same age mixing effect. Bolded lines represent the mean values. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web  version of the article.)
We have reﬁned the concept of the depletion of susceptibles for
inﬂuenza in epidemic models to incorporate partial immunity and
the differential boosting of antibodies, leading to different relation-
ships between seroprevalence and cumulative incidence during the
epidemic. A difference has been observed previously (Birrell et al.,
2011) between peak incidence inferred with a model ﬁtted to sero-
prevalence data and syndromic incidence, and was explained by
the possible changes of consulting or reporting rates. However, our
results suggest that use of threshold immunity within the epidemic
model may  have underestimated cumulative incidence, resulting in
a delay of the inferred epidemic peak, and that the two  data sources
may  be consistent when stratiﬁed immunity is taken into account.
The titre model also predicted a larger increase in seropreva-
lence for children and little increase in elderly persons. However,
the low incidence in the elderly could not be explained by
higher pre-existing antibodies, as proposed by some other studies
(Cauchemez et al., 2009; Ikonen et al., 2010), nor by low antibody
boosting. Our results support the importance of age-speciﬁc mix-
ing pattern and relative infectivity of children to adults as the key
drivers of infection heterogeneity, extending previous work show-
ing that the pre-existing titres and age group mixing alone could
not explain the age distribution of infections (Wu  et al., 2014). Cer-
tain studies have demonstrated that children were associated with
higher viral loads or prolonged shedding (Lee et al., 2011; To et al.,
2010), which may  increase the transmissibility in children.
One of the most important challenges for infectious disease
control is to monitor disease transmissibility in real time with
statistics such as the effective reproductive number R(t) (Cowling
et al., 2010; WHO  Ebola Response and Team, 2014). The titre model
structure presented here allows us to deﬁne the effective repro-
ductive number in the presence of stratiﬁed immunity, RB(t). Our
analysis suggests that the 2009 pandemic strain had an underly-
ing RB(0) of 1.22 [1.16–1.28] in the presence of the pre-existing
or cross-reactive antibodies, which is similar to but slightly lower
than R0 (1.28 [1.23–1.34]) estimated by Wu et al. (2014), when an
age-structured transmission model was ﬁtted to both seropreva-
lence and hospitalization data. In a previous study using laboratory
conﬁrmed cases in Hong Kong, the initial effective R was esti-
mated around 1.4–1.5 (Cowling et al., 2010) but the number quickly
dropped to between 0.9 and 1.3 from July and became lower than 1
90 H.-Y. Yuan et al. / Epidemics 20 (2017) 84–93
after September, which is generally consistent to RB. The difference
of RB(t) during the initial phase of the epidemic could be due to
the absence of school vacations in the model framework presented
here.
Our dynamical model with stratiﬁed immunity enables us to
reduce uncertainty in the number of infected individuals derived
from reporting rates; thus potentially providing a framework to
improve current predictive modelling of inﬂuenza, which essen-
tially relies on the estimates of ILI or relevant inﬂuenza cases
(Shaman and Karspeck, 2012; Shaman et al., 2013). Planning
and implementing intervention strategies such as vaccination, to
reduce inﬂuenza transmission is currently still a challenge (Lipsitch
et al., 2011; Baguelin et al., 2013). The framework here can be
extended to evaluate the impact of vaccination on disease transmis-
sion through antibody responses. Furthermore, it seems plausible
that this general approach can be applied to seasonal inﬂuenza
viruses and other emerging infectious diseases where partial pro-
tection may  be important, such as avian inﬂuenza, dengue, and Zika
viruses, (Duffy et al., 2009; Lanciotti et al., 2008).
4. Methods
4.1. Serological samples
We  analyzed the updated laboratory test results from the base-
line and follow-up rounds of the Hong Kong inﬂuenza serological
survey (Riley et al., 2011). Here, we used HI assay results for the
2009 pandemic strain of H1N1. We  obtained the baseline HI titres
from 523 individuals (between 4 July 2009 and 28 September 2009)
and from 465 individuals recruited during the follow-up period
(between 11 November 2009 and 6 February 2010) (Fig. S1). The
previously published analyses used only microneutralization assay
results for the subset of individuals with the paired samples. We
also noted that previous analysis was based only on 4-fold rise or
greater in paired samples and thus did not need to exclude indi-
viduals who reported vaccination prior to the baseline visit. Here,
because it was our objective to make inference on cross-sectional
patterns of serology, for our primary analyses, we excluded all indi-
viduals who reported any inﬂuenza vaccination in the preceding
years.
4.2. Transmission model
The epidemiological and serological dynamics were simulated
based on a disease transmission model with a serological response
component. The model is illustrated in Fig. S3A as an extension of
the SIRS model, where hosts are classiﬁed into discrete immune
classes, corresponding to different antibody dilution ratios ranged
from <1 :10 (undetectable titre) to 1:10 and from 1:10 to the high-
est dilution tested 1:2560. To simplify the ﬁgure, we exclude age
mixing effects in the schema. The probability of susceptible indi-
viduals being infected given a contact with an infected person was
dependent on their antibody titres. The susceptibility decreased
as the individuals’ antibody titre increased (Fig. S3B). Once the
infected individual had recovered, the antibody titre was  boosted
to a higher level according to a truncated Poisson distribution (Fig.
S3C) to capture the antibody titre proﬁle as seen in Fig. 1. At the
same time, the infected individual became transiently fully pro-
tected within 25 days on average by short-lived immunity, possibly
mediated by cytotoxic T lymphocytes with other immunological
factors (Ferguson et al., 2003; Kaech and Cui, 2012). The individ-
uals later became susceptible again after the transient immunity
waned and were assumed to be protected by only antibodies. The
epidemiological parameters we used are described in Fig. S3 and
Table S4. The variables of the titre model are listed in Table 2.
Disease dynamics are described by the following Eqs. (1)–(3) with
age mixing effects. The model did not take into account age demo-
graphics since the duration of the outbreak we  considered here was
less than one year. Birth and death rates were not included because
that the rates of 1/70 per year did not produce marked differences
in epidemic curves using the SIR model.
dSi(a)
dt
= −Si · a(i) · (a) + ω · Ri(a) (1)
dIi(a)
dt
= Si · a(i) · (a) −
1
Tg
imax∑
j=i+1
Ii(a) · gji (2)
dRi(a)
dt
= 1
Tg
i−1∑
j=0
Ij(a) · gij − ω · Ri(a) (3)
where a represents the age group for each individual, a(i) is the
disease susceptibility for susceptible individuals in age group a in
the presence of titre level with index i ranging from zero to the
maximum index value imax,  is force of infection, ω is the waning
rate for short-lived transient immunity, Tg is the duration of infec-
tion, and gji is the probability of immune boosting from titres i to
j. The force of infection on members of age class a in a completely
naive population (S0 without antibody protection) is deﬁned as
(a) = ˇ
amax∑
b=1
{mab
imax∑
i=0
fb · Ii(b)} (4)
where mab is the contact rate from age class b to a, fb=1 is the relative
infectivity of children to adults, and  ˇ is a scale factor such that
the product of ˇ, mab and fb becomes the transmission rate in an
age-structured naive population. We  stratiﬁed sera samples into
age groups, i.e. children and adolescent (<20 yo; for convenience,
we deﬁned this group as children throughout the study), young
adults (20–39 yo), mid-age adults (40–64 yo) and elders (≥65 yo).
A contact mixing matrix of the four age groups was calculated from
a community study in Hong Kong (Fig. S6).
4.3. Differential susceptibility
The susceptibility  is deﬁned as the proportion of individuals
that develop disease from infection given a particular titre level. 
is modelled as a two parameters logistic function (Dunning, 2006):
(i) = 1
1 + eIˇ(i−TP50)
(5)
where TP50 is deﬁned as the titre at which  will drop 50% from the
maximum value (Fig. S3B). Iˇ determines the shape of the curve,
which was  assumed to be 2.102 according to a previous study
(Coudeville et al., 2010). 1 − (i) is deﬁned as antibody protection.
For individuals with undetectable titre, we assume the maximum
susceptibility 100% is present.
4.4. Antibody boosting
Antibody boosting gji is deﬁned as probability of the increase
of serological titre (log scale) from titre index i to j, which is
Poisson distributed but truncated by zero with rate Abb (Clifford
Cohen, 1960) adapted from a recent serological modelling approach
(Kucharski et al., 2015):
gji =
Abbıe−Abb
ı!(1 − e−Abb) (6)
where ı equals j − i and the mean of the antibody boosting is derived
as AbB = Abb
1−e−Abb .
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Table  1
Parameters estimates from the titre model and the threshold model using MCMC.
The minimum effective sample size (ESS) is above 100 for all variables. Burn in was
1000  steps in accordance with the Geweke diagnostic test.
Models A E
R0 1.22 [1.16–1.28] 1.19 [1.16–1.25]
AbB1 5.96 [4.98–7.00] –
AbB2 4.97 [4.02–6.02] –
AbB3 3.78 [3.03–4.60] –
AbB4 4.79 [2.16–7.54] –
TP501 2.15 [0.61–5.41] –
TP502 3.40 [0.67–9.13] –
TP503 2.80 [0.60–9.05] –
TP504 5.08 [0.77–9.69] –
f1* 5.01 [3.96–5.95] 4.57 [3.63–5.58]
Note that R0 is deﬁned in the presence of the initial partial immunity here. AbB is
deﬁned as the mean of the truncated Poisson distribution. We used uniform priors
for all parameters other than f1.
* For the prior distribution of f1, we used a Gaussian distribution with mean=4
and standard deviation = 0.5 (see Fig. S7) because a 4-fold increase of viral loads was
observed for children (Lee et al., 2011).
4.5. Transmission model with threshold data
The threshold model is a special case of the titre model, in which
the titre index i ranged from 0 to only 1, corresponding to indi-
vidual seropositivity data aggregated from the serological titres
based on a threshold titre of 1:40 (dilution ratio). All susceptible
individuals (i = 0) were complete susceptible to infection. Once an
infected individual recovered, the individual became seropositive
(i = 1) and remained fully protected by antibodies, instead of being
partially protected. Susceptibility can also be described by the two
parameters logistic function (Eq. (5)), where Iˇ was  near inﬁnity
(practically a value larger than 100 was sufﬁcient) and TP50 is a
number between 0 and 1. We  were able to describe the observed
dynamics using an SIR epidemic model.
4.6. Parameters estimation
The posterior distributions of the parameters, including the
transmission rate scale factor ˇ, age dependent antibody boosting
AbBa, age dependent immune protection TP50a, and the relative
infectivity of children (versus adults) fa=1, were obtained from
Metropolis-Hastings in Markov Chain Monte Carlo (MCMC) with
106 steps (Table 1) to guarantee an effective sample size (ESS) of
greater than 100 for all parameters. Aside from the variable f1, prior
distributions for all the parameters were set to uniform distribu-
tions. The mean relative infectivity of children was set to be 4 with
a standard deviation of 0.5 compared to other age groups, based on
the assumption that infectivity was linearly correlated with viral
load, which was about 4-fold higher in children than other age
groups (Lee et al., 2011).
The starting day of the pandemic was set to 1st May  (the date of
the ﬁrst observed case in the Hong Kong pandemic). We  assumed
the number of the initial infected individuals was  10, which pro-
vided a seed size large enough to cause a major outbreak with only
a 10% chance of stochastic extinction when R0 equals 1.25 (Allen
and Lahodny, 2012; Hartﬁeld and Alizon, 2013). The initial anti-
bodies among the 40–80 and 10–20 titre groups were both set
to be 2% for all the age groups <65 and 4% in the elderly respec-
tively, representing a higher seroprevalence. Because it has been
shown that HI assay titres are generally less sensitive than MN
assay (Grund et al., 2011), this gave an approximation of 3.3% pre-
pandemic seroprevalence in Hong Kong using MN assays (Wu  et al.,
2014).
Table 2
The variables speciﬁed in the full titre model and the alternative versions of the titre
and threshold models.
Models A B C D E F
Basic reproductive number
√ √ √ √ √ √
Age-dependent Ab boosting
√ √ √
Age-dependent Ab protection
√ √ √
Relative infectivity of children
√ √ √ √
Age-independent Ab boosting
√
Age-independent Ab protection
√
DICa 0 7 −2.6 38.5 11.5 15.4
a Note that DIC was calculated as the DIC of the alternative model minus the DIC
of the full titre model (719.7).
The likelihood of observing cross-sectional serological titres was
calculated as
L(|et1, et2, . . .,  etN) =
N∏
n=1
f (etn) (7)
where N is the total number of the samples, f(etn) is the frequency of
observing titre e of the individual n from the model output with the
parameter values  at time t. The observation error was  included,
such that for each individual, the frequency of the titre e would
be the likelihood of observing titre e from all possible true titre
distributions P(i).
f (e) =
imax∑
i=0
P(i) · P(e|i) (8)
We assumed the probability of observational error was  uniformly
distributed as 0.005 for each titre i not equal to e. The sum of all
observation errors including i equal to e was 1. The imax was set to
9 corresponding to a 2560 titre. The above two  equations were also
applied to the threshold data (individual seropositivity data), aggre-
gated from the recruited serological titre proﬁle using the threshold
titre 40, with the maximum titre imax in Eq. (8) set to 1.
4.7. Model comparison
We explored the effect of age-speciﬁc antibody boosting, age-
speciﬁc antibody protection, relative infectivity of children in the
titre models and the effect of relative infectivity of children in the
threshold models (Table 2). We  compared the goodness of ﬁt of
the different models using Deviance Information Criterion (DIC)
(Spiegelhalter et al., 2002) to individual seropositivity data y, aggre-
gated from the recruited serological titre proﬁle using the threshold
titre 40. Among each model variant, the log-likelihood of observing
seropositive samples with parameters  was calculated using Eqs.
(7) and (8) where imax equals 1. DIC was  derived as DIC = PD + D¯
using 400 random samples from the posterior distributions, where
deviance D is deﬁned as −2 · log L(|y), PD equals D¯ − D¯ , D¯ is the
expectation of D, and ¯ is the expectation of .
4.8. Calculating effective reproductive number
The effective reproductive number was calculated using next
generation matrix approaches. Following the same notation as in
the study by Diekmann et al. (2010), the transmission matrix T and
the transition
∑
can be obtained. Each element in T represents the
average newly infected cases in age group a and titre index i in a
unit time transmitted by single infected individual in age group
b and titre index l, which can be calculated as ˇMabfbSi(a)a(i).∑
represents the transitions between cases in each age and titre
group. Since the probability of boosting to all other titres becomes
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one, each element in
∑
is simply the loss of infected cases due to
recovery in a unit time −1/Tg from our model.
4.9. Contact mixing
To quantify and describe the tendency of people to mix with
others of similar or different ages, an age-speciﬁc contact matrix
of participants was constructed based on four waves/rounds of
recruitment of the longitudinal telephone contact survey (Kwok
et al., 2017). Four groups for age of participant were deﬁned as
columns (2–19,20–39,40–64,65+) and four groups for age of con-
tacts (0–19,20–39,40–64,65+) were deﬁned as rows, and were
calculated based on the number of daily contacts between indi-
viduals based on their age group.
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